July 30, 2018 (Kyoto, Japan) – Kyoto University Hospital, in partnership with the Center for iPS Cell Research and Application (CiRA), Kyoto University, has planned physician-initiated clinical trials for Parkinson’s disease that transplants dopaminergic progenitors1 generated from induced pluripotent stem (iPS) cells. The clinical trial notification was submitted to the Pharmaceutical and Medical Devices Agency (PMDA; the Japanese equivalent of the FDA) on June 4, 2018, and the clinical trials are scheduled to begin on August 1 this year. [Read more…]
Cymerus™ MSC treatment leads to improved recovery of cardiac function in preclinical heart attack study
Melbourne, Australia; 31 July 2018: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a preclinical heart attack model. [Read more…]
RichSource Stem Cells, Inc. Announces Non-Invasive Breakthrough Product RICHGEN
August 1, 2018 – Charleston, SC, USA – RichSource Stem Cells, Inc. (RichSource), a leader in the business development and distribution of human tissue allograft combination products and membranes, announced today its own brand product line: RICHGEN. With the introduction of this breakthrough line, the industry is no longer limited to single material post-birth, multipotent cellular products. Available throughout the U.S., the RICHGEN product line is backed by an experienced nationwide team of RichSource Area Vice Presidents who can educate, train and provide support to physician practices and networks. Additionally, RichSource’s simplified and more effective treatment protocols helps to optimize practices and patient results. [Read more…]
Fresenius Medical Care achieves preclinical milestone in its regenerative medicine program for chronic kidney disease
July 30, 2018 – Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that its subsidiary Unicyte AG has achieved a key preclinical milestone in its regenerative medicine program for chronic kidney disease. The company was able to confirm a disease modifying potential for its proprietary nano-Extracellular Vesicles (“nEVs” are stem cell-derived particles that support communication between cells) in a second preclinical model of chronic kidney disease. [Read more…]
University of Miami Researchers Present the Latest at the American Association of Stem Cell Physicians (AAOSCP) Annual Summit
August 16, 2018, Miami, FL — The American Association of Stem Cell Physicians (AAOSCP) concluded a highly successful annual summit held from August 10 – 12, 2018, in Miami, FL. Attended by a global audience, the event featured researchers from the University of Miami who presented the latest research on stem cell applications.
The spokesperson for American Association of Stem Cell Physicians, A.J. Farshchian, MD, stated: “The American Association of Stem Cell Physicians is solely committed to create an educational platform based on solid foundational research. Our goal is to enhance the quality of medical practice and the continued education of physicians. [Read more…]
- « Previous Page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- …
- 96
- Next Page »